Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2010-06-01
2011-11-15
Kosack, Joseph (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S336000, C514S355000, C514S448000, C514S471000, C514S575000, C544S168000, C546S280400, C546S315000, C549S057000, C549S072000, C549S468000, C549S488000, C562S621000
Reexamination Certificate
active
08058273
ABSTRACT:
New inhibitors of histone deacetylases having antitumor activity, and the process of preparation thereof are herein described. These compounds belong to the structural formula (I)where R1is a linear or branched chain containing at least two conjugated double bonds, A is an optionally substituted phenyl or pyridyl ring, Ar is an aryl or heteroaryl group, and R3is hydrogen or alkoxyalkyl. The application also describes the use of said compounds in the treatment of diseases associated to the deregulation of histone deacetylases activity, such as tumors, as well as the relevant pharmaceutical compositions for administration to patients requiring said treatment.
REFERENCES:
patent: 95/13264 (1995-05-01), None
patent: 01/38322 (2001-05-01), None
patent: 02/22577 (2002-03-01), None
patent: 02/26696 (2002-04-01), None
patent: 02/30879 (2002-04-01), None
patent: 03/087066 (2003-10-01), None
patent: 2004/063169 (2004-07-01), None
patent: 2005/040101 (2005-05-01), None
patent: 2005/040161 (2005-05-01), None
patent: 2006/037761 (2006-04-01), None
patent: 2007/113249 (2007-10-01), None
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, vol. 286, Oct. 15, 1999, pp. 531-537.
Lin et al. “Transcriptional regulation in acute promyelocytic leukemia” Oncogene, 2001, vol. 20, pp. 7204-7215.
Grignani et al. “Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukaemia” Nature, 1998, vol. 391, pp. 815-818.
Lutterbach et al. “ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors” Mol. Cell. Biol., 1998; vol. 18, pp. 7176-7184.
James R Davie, “Covalent modifications of histones: expression from chromatin templates,” Current Opinion in Genetics & Development, 1998, 173-178, vol. 8, Current Biology Ltd ISSN 0959-437X.
Jiansheng Wu et al., “25 years after the nucleosome model: chromatin modifications,” TIBS 25, Dec. 2000, 619-623, Elsevier Science Ltd.
Richard J Lin et al., “Transcriptional regulation in acute promyelocytic leukemia,” Oncogene, 2001, 7204-7215, vol. 20, Nature Publishing Group.
Arthur Zelent et al., “Translocations of the RAR∝ gene in acute promyelocytic leukemia,” Oncogene, 2001, 7186-7203, vol. 20, Nature Publishing Group.
Pier Paolo Pandolfi, “Transcription therapy for cancer,” Oncogene, 2001, 3116-3127, vol. 20, Nature Publishing Group.
Francesco Grignani et al., “Fusion proteins of the retinoic acid receptor-∝ recruit histone deacetylase in promyelocytic leukaemia,” Nature, Feb. 19, 1998, 815-818, vol. 391, MacMillan Publishers Ltd.
Bart Lutterbach et al., “ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors,” Molecular and Cellular Biology, Dec. 1998, 7176-7184, vol. 18, No. 12, American Society for Microbiology.
Robert J Ferrante et al., “Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice,” The Journal of Neuroscience, Oct. 15, 2003, 9418-9427, vol. 23, No. 28, Society for Neuroscience.
Emma Hockly et al., “Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease,” PNAS, Feb. 18, 2003, 2041-2046, vol. 100, No. 4.
Robin S B Williams et al., “A common mechanism of action for three mood-stabilizing drugs,” Nature, May 16, 2002, 292-295, vol. 417, MacMillan Magazines Ltd.
Erminio Costa et al., “GABAergic Cortical Neuron Chromatin as a Putative Target to Treat Schizophrenia Vulnerability,” Critical Reviews in Neurobiology, 2003, 121-142, vol. 15, No. 2.
Simon P. Chandler et al., “Fragile X (CGG)n repeats induce a transcriptional repression in cis upon a linked promoter: Evidence for a chromatin mediated effect,” BMC Molecular Biology, Mar. 21, 2003, vol. 4, No. 3, BMC Molecular Biology.
Pietro Chiurazzi et al., “Synergistic effect of histone hyperacetylation and DNA demethylation in the reactivation of the FMR1 gene,” Human Molecular Genetics, 1999, 2317-2323, vol. 8, No. 12, Oxford University Press.
L Bodai et al., “Altered Protein Acetylation in Polyglutamine Diseases,” Current Medicinal Chemistry, 2003, 2577-2587, vol. 10, Bentham Science Publishers Ltd.
Robert E Hughes, “Polyglutamine Disease: Acetyltransferases Awry,” Current Biology, Feb. 19, 2002, R141-R143, vol. 12, Elsevier Science Ltd.
Mi Ra Jeong et al., “Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition,” FEBS Letters, 2003, 74-78, vol. 542, Elsevier Science B.V.
Ming Ren et al., “Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction,” Journal of Neurochemistry, 2004, 1358-1367, vol. 89, International Society for Neurochemistry.
Hoon Ryu et al., “Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway,” PNAS, Apr. 1, 2003, 4281-4286, vol. 100, No. 7.
Tiina Suuronen et al., “Regulation of microglial inflammatory response by histone deacetylase inhibitors,” Journal of Neurochemistry, 2003, 407-416, vol. 87, International Society for Neurochemistry.
Sara Eyal et al., “The Activity of Antiepileptic Drugs as Histone Deacetylase Inhibitors,” Epilepsia, 2004, 737-744, vol. 45, No. 7, Blackwell Publishing Inc, International League Against Epilepsy.
Yunfei Huang et al., “Altered Histone Acetylation at Glutamate Receptor 2 and Brain-Derived Neurotrophic Factor Genes Is an Early Event Triggered by Status Epilepticus,” The Journal of Neuroscience, Oct. 1, 2002, 8422-8428, vol. 22, No. 19, Society for Neuroscience.
Lisa J Corcoran et al., “A Novel Action of Histone Deacetylase Inhibitors in a Protein Aggresome Disease Model,” Current Biology, Mar. 23, 2004, 488-492, vol. 14, Elsevier Ltd.
Emmanuelle Adam et al., “Potentiation of Tumor Necrosis Factor-Induced NF-kB Activation by Deacetylase Inhibitors Is Associated with a Delayed Cytoplasmic Reappearance of IkB∝,” Molecular and Cellular Biology, Sep. 2003, 6200-6209, vol. 23, No. 17, American Society for Microbiology.
Carine Van Lint et al., “Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation,” The EMBO Journal, 1996, 1112-1120, vol. 15, No. 5, Oxford University Press.
Dominique Demonte et al., “Administration of HDAC inhibitors to reactivate HIV-1 expression in latent cellular reservoirs: implications for the development of therapeutic strategies,” Biochemical Pharmacology, 2004, 1231-1238, vol. 68, Elsevier Inc.
Loyda Ylisastigui et al., “Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression,” AIDS, 2004, 1101-1108, vol. 18, Lippincott Williams & Wilkins.
Soren Skov et al., “Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression,” Blood, Feb. 15, 2003, 1430-1438, vol. 101, No. 4, The American Society of Hematology.
Pavan Reddy et al., “Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect,” PNAS, Mar. 16, 2004, 3921-3926, vol. 101, No. 11, The National Academy of Sciences of the USA.
Hyun Kook et al., “Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop,” The Journal of Clinical Investigation, Sep.
Ballarini Marco
Gargiulo Gaetano
Mai Antonello
Massa Silvio
Minucci Saverio
DAC S.R.L.
Kosack Joseph
McCormick Paulding & Huber LLP
LandOfFree
Histone deacetylases inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histone deacetylases inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histone deacetylases inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4312347